SOURCELIST
“WEIGHING THE EVIDENCE: Conducting Reviews of
Pharmaceuticals in Four Countries”
April 22, 2005
Washington, D.C.
Speakers
Marc Berger, Merck & Co., Inc. …………………………………………... 215/652-5861
Mark Gibson, Drug Effectiveness Review Project, OHSU…………….……503/494-2679
Andreas Laupacis, Institute for Clinical Evaluative Sciences……….alaupacis@ices.on.ca
Peter Littlejohns, NICE, UK…………………...……………peter.littlejohns@nice.nhs.uk
Robin Osborn, The Commonwealth Fund…………...………………………212/606-3800
Peter Sawicki, Inst. for Quality and Economic Efficiency….…peter.sawicki@+-online.de
Government Agencies and Related Organizations
Janet Corrigan, Institute of Medicine……………………………….………. 202/334-2165
David Hunt, Centers for Medicare and Medicaid Services………….……...410/786-9354
Karen Migdail, Agency for Healthcare Research and Quality ……………..301/427-1855
Dennis S. O’Leary, Joint Comm. on Accreditation of Healthcare Org……..630/792-5650
Jonathan B. Perlin, Dept. of Veterans Affairs……...…………..………….…202/273-5781
Richard Price, Congressional Research Service………………..………...…202/707-7370
Analysts
Stuart Altman, Brandeis University Institute for Health Policy……….…....781/736-3803
Gerard Anderson, Johns Hopkins University………………………………..410/955-3241
Diane Archer, Medicare Rights Center……………………………………...212/869-3850
Donald Berwick, Institute for Healthcare Improvement……………………617/301-4800
David Blumenthal, Inst. for Health Policy, Mass. Gen. Hosp.……………...617/726-5212
Stuart Butler, The Heritage Foundation…………………………..…….…. 202/546-4400
Tanisha Carino, Health Strategies Consultancy………………………..……202/207-3677
Cheryl Damberg, RAND………………………………………….…..310/393-0411 x6191
Karen Davis, Commonwealth Fund…………………………………..……..212/606-3800
Richard Deutsch, The American Health Quality Association………….……202/261-7573
Arnold Epstein, Harvard School of Public Health……..………………..…..617/432-3415
Timothy Ferris, Inst. for Health Policy, Mass. Gen. Hosp.…………….…....617/724-4744
Beth Fuchs, Health Policy Alternatives…………………………………..…202/737-3390
David Gross, AARP Public Policy Institute…………………………………202/434-3840
John Iglehart, Health Affairs……………………………..….………………301/656-7401
Risa Lavizzo-Mourey, Robert Wood Johnson Foundation……...…………..888/631-9989
Arthur Aaron Levin, Center for Medical Consumers………………….212/674-7105 x22
Ellie MacDonald, Inst. for Health Policy, Mass. Gen. Hosp....…….……….617/724-7016
Tricia Neuman, Kaiser Family Foundation, Medicare Policy Project..…….202/347-5270
Margaret O’Kane, National Committee for Quality Assurance……….…….202/955-3500
Francis Palumbo, U. of Maryland’s Center on Drugs and Public Policy…...410/706-2303
Diane Pinakiewicz, National Patient Safety Foundation…………….……...703/506-3280
John Rother, AARP……………………………………………………….….202/434-3701
Cathy Schoen, Commonwealth Fund………………………………………..212/606-3800
David Schulke, The American Health Quality Association…………………202/331-5790
Gail Shearer, Consumers Union……………………………………...……...202/462-6262
John Tooker, American College of Physicians……………………………...215/351-2800
Bill Vaughan, Families USA……………………………………..……….…202/628-3030
Robert M. Wachter, University of California, San Francisco…….. ……….415/476-5632
Alan R. Weil, National Academy for State Health Policy…………………..207/822-3911
Gail Wilensky, Project HOPE……………………………………….……...301/656-7401
Stakeholders
John Coster, National Association of Chain Drugstores……………......…..703/549-3001
Jack Ebeler, Alliance of Community Health Plans…………………....……..202/785-2247
Karen Ignagni, America’s Health Insurance Plans …..……………….…….202/778-3200
Charles (Chip) Kahn, Federation of American Hospitals…………………...202/624-1534
Mary Nell Lehnhard, Blue Cross Blue Shield Association………….…….....202/626-4781
Ed Mihalski, Eli Lilly………………………………………………….…….202/434-1020
John C. Nelson, American Medical Association………………………….… 800/621-8335
Donald M. Nielsen, American Hospital Association…………………….…..312/422-2708
Anthony Principi, Pfizer……………………………………………………..202/783-7070
Rick Smith, PhRMA……………………………………………………..…..202/835-3400
Ian Spatz, Merck and Company……………………………………………..202/638-4170
Websites
AARP, Effectiveness and Safety of Prescrip. Drugs....www.aarp.org/health/comparedrugs/
Access to Benefits Coalition……………………………. http://www.accesstobenefits.org/
AHRQ’s Centers for Education and Research on Therapeutics..http://www.certs.hhs.gov/
Alberta Heritage Fdn. for Medical Research…………………....……... www.ahfmr.ab.ca
Alliance for Health Reform……………………………………………. www.allhealth.org
California HealthCare Foundation…………….…………….….………….www.chcf.org
Canadian Commission On Health Technology Assessment (CCOHTA)…..www.ccohta.ca
Centers for Medicare and Medicaid Services……………………...………..www.cms.gov
Centre for Evidence-based Medicine (UK). ……………………………….www.cebm.net
Centre for Health Evidence (UK)…………….…………………….cche.net/che/home.asp
Consumer Reports…………………………………….……... www.CRBestBuyDrugs.org
Department of Veterans Affairs……………………………….………………www.va.gov
Drug Effectiveness Review Project……………….…….www.ohsu.edu/drugeffectiveness
German Inst. for Quality and Economic Efficiency (IQWiG –In German)…www.iqwig.de
Government of British Columbia, PharmaCare Reference Drug Program
…………………………………www.healthservices.gov.bc.ca/pharme/rdp/rdpindex.html
Health Affairs……………………………………………..……….. www.healthaffairs.org
HHS National Coordinator for Health Information Tech.….………www.hhs.gov/healthit
Institute for Healthcare Improvement……………………………………..www.ihi.org/ihi
Medical Tech. & Practice Patterns Inst……….www.mtppi.org/frameset.asp?Pg=/&MI=1
National Committee on Quality Assurance…………………..….….………www.ncqa.org
National Guideline Clearinghouse……………...……………………..www.guideline.gov
National Institute for Clinical Excellence (UK)...………………………..www.nice.org.uk